Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR 1,000.60
-30.50 (-2.96%)
At close: Aug 1, 2025, 3:30 PM IST
Alivus Life Sciences Revenue
In the fiscal year ending March 31, 2025, Alivus Life Sciences had annual revenue of 23.87B INR with 4.54% growth. Alivus Life Sciences had revenue of 6.50B in the quarter ending March 31, 2025, with 21.05% growth.
Revenue
23.87B
Revenue Growth
+4.54%
P/S Ratio
5.10
Revenue / Employee
11.93M
Employees
2,014
Market Cap
122.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 23.87B | 1.04B | 4.54% |
| Mar 31, 2024 | 22.83B | 1.22B | 5.64% |
| Mar 31, 2023 | 21.61B | 380.06M | 1.79% |
| Mar 31, 2022 | 21.23B | 2.38B | 12.63% |
| Mar 31, 2021 | 18.85B | 3.48B | 22.63% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.86B |